Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

FDA approves Cimzia as treatment for Crohn's disease

A new drug has been approved to help sufferers of Crohn's disease, the U.S. Food and Drug Administration announced today. Cimzia (certolizumab pegol) received approval for adults with moderate to severe Crohn's disease who have not responded to conventional therapies. This product was approved with a Medication Guide.

22 Apr 2008

Boys are twice as likely as girls in the U.S. and Asia to receive growth hormone

Boys are twice as likely as girls in the U.S. and Asia (mostly Japan) to receive recombinant human growth hormone (rhGH) for growth hormone deficiency, illnesses that affect height, and short stature of a non-medical nature.

17 Apr 2008

Takeda to acquire Millennium for $8.8 billion

Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share.

10 Apr 2008

Omega-3 fatty acids ineffective for managing Crohn's disease

An international study led by Dr. Brian Feagan of Robarts Research Institute at The University of Western Ontario in London, Canada has found that omega-3 fatty acids are ineffective for managing Crohn's disease.

9 Apr 2008

Study identifies infection risks for patients with inflammatory bowel disease

A new Mayo Clinic study finds that patients who are 50 or older and take multiple immunosuppressive medications for inflammatory bowel disease have a higher risk for developing infections. The study is published in this month's issue of Gastroenterology.

3 Apr 2008

Potential new genetic markers for Crohn's disease

What is believed to be the largest study of its kind for the genetic roots of inflammatory bowel diseases has suggested new links to Crohn's Disease as well as further evidence that some people of Jewish descent are more likely to develop it.

28 Mar 2008

The effect of melatonin on colitis

In rats with experimental colitis, the marked increase in bacterial translocation in postcolitis rats has been reversed by melatonin administration.

19 Mar 2008

How do infections and toxins launch a cell's self-destruct and alarm system?

Cells are coded with several programs for self-destruction.

11 Mar 2008

Colon cancer treatment, symptoms, clinical trials

Fewer people are dying from colorectal cancer, but it remains the third deadliest form of cancer in America.

4 Mar 2008

Children's Hospital 1 of 10 pediatric hospitals in US selected to study liver disease in kids

Children's Hospital of Pittsburgh of UPMC has been selected to join an effort among select centers in the United States and Canada to collect and study information necessary to understand the possible causes and treatment of a destructive liver disease called primary sclerosing cholangitis (PSC).

27 Feb 2008

Quality of care for inflammatory bowel disease patients can be improved

Inflammatory bowel disease (IBD) is a chronic recurrent gastrointestinal disease.

26 Feb 2008

Scorpion venom may hold key to controlling cystic fibrosis

Researchers have discovered a peptide in scorpion venom that may hold the key to understanding and controlling cystic fibrosis and other secretory diseases.

17 Feb 2008

Discovery of possible target for prevention and treatment of pneumonia

Researchers at Children's Hospital of Pittsburgh of UPMC have identified a key protein target that may be a crucial factor in the development of a vaccine to prevent and new therapies to treat pneumonia, the leading killer of children worldwide.

12 Feb 2008

Potential new treatment for inflammatory bowel disease

Irish scientists have discovered a new potential therapeutic approach to Inflammatory Bowel Disease (IBD), a chronic debilitating disease involving inflammation of the intestine which affects more than 15,000 people in Ireland and millions of people worldwide.

15 Jan 2008

FDA approves Tysabri to treat Crohn's disease

The U.S. Food and Drug Administration has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies.

14 Jan 2008

Il-22 gene delivers the goods and decreases intestinal inflammation

There are two major types of inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC).

3 Jan 2008

ACG offers updated clinical guidance for managing pregnant patients

Physician experts from the American College of Gastroenterology have released an updated educational monograph highlighting the unique clinical challenges of caring for women with chronic digestive disorders during pregnancy and managing GI complications relating to pregnancy.

10 Dec 2007